Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Around the Web — 3.15.23

Children 6 months to 4 years of age are now eligible to receive a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, as a result of yesterday’s amendment of the product’s emergency use authorization (EUA) by the FDA. Boosters can be administered 2 months following completion of the primary vaccination with 3 doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine.

Increased risks of myocarditis and pericarditis have been reported following vaccination with the Janssen COVID-19 Vaccine, particularly within the first 7 days after administration, FDA warned earlier this week. A revised EUA includes information on the occurrence of facial paralysis (including Bell’s palsy) and on its use as a first booster dose at least 2 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine.

Trending on the PNN website in recent weeks are these posts:

2023 Adult Immunization Schedule

NIH Updates the COVID-19 Treatment Guidelines

FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries

Antipsychotic Use in Treatment-Resistant Depression

Inflammation, Hypercholesterolemia as CVD Event Predictors During Statin Therapy